New cytokine targets in inflammatory bowel disease

Gastroenterology and Hepatology

Volumn 7, Issue 7, 2011, Pages 474-476

  MacDonald, Thomas T ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84894269592     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. Colombel JF, Sandborn WJ, Reinisch W, et al SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
2. Fantini MC, Monteleone G, MacDonald TT. IL-21 comes of age as a regulator of effector T cells in the gut. Mucosal Immunol. 2008;1:110-115.
3. MacDonald TT, Monteleone I, Fantini MC, Monteleone G. Regulation of homeostasis and inflammation in the intestine. Gastroenterology. 2011;140:1768-1775.
4. MacDonald TT. Inside the microbial and immune labyrinth: totally gutted. Nat Med. 2010;16:1194-1195.
5. Sandborn WJ, Feagan BG, Fedorak RN, et al Ustekinumab Crohn's Disease Study Group. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 2008;135:1130-1141.